Gedeon Richter UK Ltd: UK Public Sector Contracts Won & Awards
Companies House: Private Limited Company·London·Nationwide (UK)·Main market: Pharmaceutical products
Official UK PPONPVNN-9371-ZTBW
i
How many tenders this supplier has won.
Tenders with at least one award to it. Award records are shown too, because one framework can carry many call-offs.
i
How many different public bodies have awarded to this supplier.
Buyers named on its awards, with duplicate names merged.
i
How much this supplier has won, by published values.
Sum of award values where it was the only winner, VAT excluded, framework ceilings left out.
Not turnover. Not every award publishes a value.
i
Awards to this supplier in the last 12 months.
Award records dated in the last 12 months, against the two years before.
i
Contracts that finish in the next 18 months.
Contracts ending in that window by the published end date or, where only a duration is published, an estimate from signature plus duration (marked). Neither, not counted.
An end date does not confirm a new procurement.
i
In which regions this supplier wins work.
The region of each buyer it won from: the buyer’s office, placed by the official ONS postcode lookup. Each procedure counts once.
Where the buyer is based, not necessarily where the work was done; the tender page shows the published place of delivery.
Where they wini
In which categories this supplier wins.
Distinct awards by the main category of the lot, or of the procedure when no lot is named. Repeat publications count once.
An award counts once in each class it covers; classes can overlap.
i
In which categories this supplier wins.
Distinct awards by the main category of the lot, or of the procedure when no lot is named. Repeat publications count once.
An award counts once in each class it covers; classes can overlap.
49 awards (48 for a named lot, 98%, 1 for a whole procedure with no lot named) · top CPV classes, shares of all 49 awards. An award may cover more than one class.
3360 Pharmaceutical products49 awards · 100% · 48 awards naming a lot + 1 whole-procedure awardsi
How much this supplier has won, by published values.
Sum of award values where it was the only winner, VAT excluded, framework ceilings left out.
Not turnover. Not every award publishes a value.
Largest published awards iThe biggest published awards. Awards to a single supplier with a published value, largest first, so you can check the totals against the notice. A repeated framework total can appear here. Open the notice to check. | Authority | Awarded | Term | Published value |
|---|---|---|---|---|
| Biologic and Biosimilar Medicines | eTenderwales | — | — | £1,944,200 † |
| Proprietary Drugs | eTenderwales | — | — | £25,800 † |
Where their buyers arei
In which regions this supplier wins work.
The region of each buyer it won from: the buyer’s office, placed by the official ONS postcode lookup. Each procedure counts once.
Where the buyer is based, not necessarily where the work was done; the tender page shows the published place of delivery.
i
In which regions this supplier wins work.
The region of each buyer it won from: the buyer’s office, placed by the official ONS postcode lookup. Each procedure counts once.
Where the buyer is based, not necessarily where the work was done; the tender page shows the published place of delivery.
ITL1 region of the buyer office · known for 36 of 36 awarded procedures · each procedure counts once
Bidding recordi
Competitions this supplier is known to have bid in.
Lots on Procurement Act 2023 award notices naming it as a bidder, split into won and lost. The lot is the contest: three lots of a ten-lot notice is three wins and seven losses.
i
Competitions this supplier is known to have bid in.
Lots on Procurement Act 2023 award notices naming it as a bidder, split into won and lost. The lot is the contest: three lots of a ten-lot notice is three wins and seven losses.
Procurement Act 2023 award notices name every bidder · 4 notices name this supplier, covering 5 lots since 20 Aug 2025 · observed bids, not an estimate
i
Competitions this supplier is known to have bid in.
Lots on Procurement Act 2023 award notices naming it as a bidder, split into won and lost. The lot is the contest: three lots of a ten-lot notice is three wins and seven losses.
i
Frameworks and DPS this supplier got onto.
Lots appointed out of lots applied for. Kept apart from contract wins because almost every compliant bidder gets a place.
i
How many public bodies this supplier has bid to.
Buyers on notices that name it as a bidder, win or lose.
| Notice | Authority | Outcome | Bidders | Published |
|---|---|---|---|---|
| NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026 | NHS England | appointed | 25 | 21 Jul 2026 |
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 | NHS England | appointedall 2 lots bid for | 26 | 10 Jul 2026 |
| NHS National Framework for Denosumab Injection commencing 1st January 2026 | NHS England | appointed | 13 | 4 Dec 2025 |
| NHS National Framework for Transition products (Nilotinib and Ticagrelor) | NHS England | not appointed | 17 | 20 Aug 2025 |
Bidder names come from Procurement Act 2023 award notices, which list every bidder (from 2025). Older notices name no bidders, so earlier contests do not appear here. Latest ten notices shown.
Who they sell toi
Which public bodies award work to this supplier.
Authorities named on its published awards, ranked by distinct procedures, duplicate names merged.
i
Which public bodies award work to this supplier.
Authorities named on its published awards, ranked by distinct procedures, duplicate names merged.
Authorities named on this supplier’s published awards · ranked by distinct procedures · a framework or DPS adds one award record per appointed supplier
i
What kinds of public bodies award work to this supplier.
Its award records by the authority’s published type, otherwise by its name. One framework can add many records.
NHS & health65%(32 awards)
32 of 49 awards are NHS & health (65%).Central government20%(10 awards)
10 of 49 awards are Central government (20%).Type not classified14%(7 awards)
7 of 49 awards are Type not classified (14%).
| Authority | Procedures | Share | Award records | Last activity |
|---|---|---|---|---|
| NHS England | 16 | 44.4% | 24 | 6 Jul 2026 |
| The NHS Commissioning Board (operating under the name of NHS England) | 4 | 11.1% | 4 | 7 Feb 2022 |
| NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) | 3 | 8.3% | 3 | 4 Jun 2026 |
| The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) | 2 | 5.6% | 4 | 18 Dec 2025 |
| The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority") | 2 | 5.6% | 3 | 21 Dec 2022 |
| eTenderwales | 2 | 5.6% | 2 | 17 Jun 2025 |
| The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") | 2 | 5.6% | 2 | 21 Jun 2023 |
| Procurement and Logistics Service | 1 | 2.8% | 2 | 1 Jul 2021 |
Share = of the 36 procedures with an award naming this supplier. Last activity = award date, or notice publication when no award date was published.
Contracts endingi
Contracts that finish in the next 18 months.
Contracts ending in that window by the published end date or, where only a duration is published, an estimate from signature plus duration (marked). Neither, not counted.
An end date does not confirm a new procurement.
i
Contracts that finish in the next 18 months.
Contracts ending in that window by the published end date or, where only a duration is published, an estimate from signature plus duration (marked). Neither, not counted.
An end date does not confirm a new procurement.
41 of 49 awards carry an end date, 9 estimated from the duration · not a retender forecast
| Contract | Ends | Published value |
|---|---|---|
| Lot 1 - Follitropin Alfa | 30 Nov 2026 estimated | £2,190,252 |
| Lot 5 - Gonadotrophin Releasing Hormone - GNRH Antagonists | 30 Nov 2026 estimated | £613,944 |
| Lot 1 - CM/TNS/25/5725/01 | 31 Dec 2026 | £37,694,000 |
| Cancer Medicines (Group 2) | 31 Jan 2027 | £18,207,081 |
| NP49425 Generic and Biosimilar Transition Medicines | 28 Feb 2027 | £64,103,740 |
| Medicinal Products - Direct to Trust | 2 Jun 2027 estimated | £210,000,000 |
| Medicinal Products - with Pharma Funded Homecare Services | 2 Jun 2027 estimated | £174,000,000 |
| Teriparatide Injections | 21 Jun 2027 estimated | £5,380,700 |
| Denosumab (Osteoporosis) and Ferric Carboxymaltose | 31 Jul 2027 | £2,254,091 |
| Lot 2 - CM/PHR/25/5731/02 - Ustekinumab NOFE & MAE | 31 Aug 2027 | £18,903,212 |
Soonest 10 of 11.
Recent awards
Latest 30 of 49 award records naming this supplier
About this data
- Source. Official UK public procurement notices (Find a Tender), reused under the Open Government Licence v3.0. New notices arrive through the day; the figures are rebuilt nightly.
- One profile per supplier. Built from award and contract notices that name this supplier; different spellings and registration numbers of the same company are merged into this profile.
- Values are published values. The table mirrors what the notice published: framework ceilings and joint awards are labelled and never counted as this supplier's money, and † marks a value taken from the contract notice when the award published none. Only awards made to this supplier alone count towards its value, excluding VAT. It is not turnover.
- Regions on this page are where the work is delivered, not the supplier’s registered address.
- Contract end dates. Published on 32 of 49 awards, estimated from the published duration on 9 more (marked “estimated”); those feed “Contracts ending”.
- Every figure shows what it rests on. Not every notice publishes a bid count, a value or a delivery region, so each figure carries the number of records behind it, and one built on few records is marked as such. The on a figure explains it; the counting rules are in the methodology. Spotted something wrong? Tell us.